Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experience with perindopril in normal volunteers.

B Waeber1, J Nussberger, L Perret

  • 1Division of Hypertension, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Clinical and Experimental Hypertension. Part A, Theory and Practice
|January 1, 1989
PubMed
Summary

The new oral angiotensin converting enzyme (ACE) inhibitor, perindopril, effectively reduces blood pressure responses. Administered in doses of 4-16 mg daily, it shows sustained ACE inhibition and is well-tolerated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Triple-combination therapy in the treatment of hypertension: a review of the evidence.

Journal of human hypertension·2017
Same author

Archives of gynecology and obstetrics·2016
Same author

PP125. High mobility group box 1 protein (HMGB1): A pathogenic role in preeclampsia?

Pregnancy hypertension·2015
Same author

Physiological response to whole-body vibration in athletes and sedentary subjects.

Physiological research·2014
Same author

High mobility group box 1 protein (HMGB-1): a pathogenic role in preeclampsia?

Placenta·2014
Same author

[Hypertension. Effects of antihypertensive therapy on cognitive functions].

Revue medicale suisse·2013

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Background:

  • Angiotensin converting enzyme (ACE) inhibitors are crucial in managing cardiovascular conditions.
  • Perindopril is a novel, orally active ACE inhibitor.
  • Understanding its pharmacokinetic and pharmacodynamic profile is essential for clinical application.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of perindopril in normotensive men.
  • To determine the dose-dependent effects of perindopril on the renin-angiotensin system.
  • To assess the duration of ACE inhibition and potential drug accumulation.

Main Methods:

  • Administration of single oral doses of perindopril (2-16 mg) once daily for up to one week.
  • Measurement of plasma ACE activity to assess drug-induced inhibition.

Related Experiment Videos

  • Monitoring of plasma levels of angiotensin I, angiotensin II, aldosterone, and plasma renin activity.
  • Evaluation of blood pressure and heart rate changes.

    • Main Results:

    • Perindopril demonstrated dose-dependent blunting of the pressor response to angiotensin I.
    • Maximal ACE inhibition occurred 4-8 hours post-dose, with significant reduction lasting 24 hours.
    • Decreased plasma angiotensin II and aldosterone levels were observed, with increased plasma renin activity and angiotensin I during peak inhibition.
    • No consistent changes in blood pressure or heart rate were noted, and no drug accumulation occurred with repeated administration.

    Conclusions:

    • Perindopril is an effective, long-acting oral ACE inhibitor in the 4-16 mg daily dose range.
    • The drug is well-tolerated with no significant adverse effects on routine laboratory tests.
    • Perindopril's pharmacokinetic and pharmacodynamic profile supports its use in clinical settings.